Search

Search results

755 results found

Severe neonatal anemia increases intestinal permeability by disrupting epithelial adherens junctions.

MohanKumar, Krishnan, Kopperuncholan Namachivayam, Nithya Sivakumar, Natascha G Alves, Venkataramana Sidhaye, Jayanta K Das, Yerin Chung, Jerome W Breslin, and Akhil Maheshwari. 2020. “Severe Neonatal Anemia Increases Intestinal Permeability by Disrupting Epithelial Adherens Junctions.”. American Journal of Physiology. Gastrointestinal and Liver Physiology 318 (4): G705-G716.

for the P2B Study Group. Double-Blind Study comparing P2B001 (combination of low-doses of extended-release Pramipexole and Rasagiline) to components and to optimised doses of Pramipexole-extended release in early Parkinson’s Disease.

Hauser, RA, CW Olanow, D Burdick, R Dhall, JA de Marcaida, RA Gil, DL Kreitzman, L Elmer, A McGarry, and K Kieburtz. 2024. “For the P2B Study Group. Double-Blind Study Comparing P2B001 (combination of Low-Doses of Extended-Release Pramipexole and Rasagiline) to Components and to Optimised Doses of Pramipexole-Extended Release in Early Parkinson’s Disease.”. . Mov Disord. 2024 Feb;39(2):350-359. Doi: 10.1002/Mds.29642. Epub 2023 Oct 27. PMID: 37886872.

Continuous subcutaneous foslevodopa/foscarbidopa infusion for the treatment of motor fluctuations in Parkinson's disease: Considerations for initiation and maintenance.

Fung, VSC, J Aldred, MP Arroyo, F Bergquist, RA Hauser, M Bouchard, S Bray, et al. 2024. “Continuous Subcutaneous Foslevodopa/Foscarbidopa Infusion for the Treatment of Motor Fluctuations in Parkinson’s Disease: Considerations for Initiation and Maintenance.”. . Clin Park Relat Disord. 2024 Feb 10;10:100239. Doi: 10.1016/J.prdoa.2024.100239. ECollection 2024. PMID: 38419617.

OFF-times before, during, and after nighttime sleep periods in Parkinson's disease patients with motor fluctuations and the effects of opicapone: A post hoc analysis of diary data from BIPARK-1 and -2.

Hauser, RA, A Videnovic, P Soares-da-Silva, GS Liang, K Olson, E Jen, JF Rocha, and O Klepitskaya. 2024. “OFF-Times Before, During, and After Nighttime Sleep Periods in Parkinson’s Disease Patients With Motor Fluctuations and the Effects of Opicapone: A Post Hoc Analysis of Diary Data from BIPARK-1 and -2.”. Parkinsonism Relat Disord. 2024 Jun;123:106971. Doi: 10.1016/J.Parkreldis.2024.106971. Epub 2024 Apr 9.PMID: 38631081.

Members of the IPMDS Rating Scales Review Committee. Scales for Antipsychotic-Associated Movement Disorders: Systematic Review, Critique, and Recommendations. 2023 Jun;38(6):1008-1026. doi: 10.1002/mds.29392. Epub 2023 Apr 20. PMID: 37081740

Durability of the Clinical Benefit of Droxidopa for Neurogenic Orthostatic Hypotension During 12 Weeks of Open-Label Treatment. Neurol Ther. 2022 Mar;11(1):459-469. doi: 10.1007/s40120-021-00317-5. Epub 2022 Feb 2. PMID: 35107750.

P2B001 (Extended Release Pramipexole and Rasagiline): A New Treatment Option in Development for Parkinson's Disease. Adv Ther. 2022 May;39(5):1881-1894. doi: 10.1007/s12325-022-02097-2. Epub 2022 Mar 10. PMID: 35267155.